Pregabalin Capsule
Product Images NDC 50090-5071

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905071)

Product No. 1920990-207 is a pack of 90 capsules of Pregabalin with a strength of 75mg. The storage temperature for this product is 77 degrees Fahrenheit.*

FDA Label Image

Equation (Pregabain Gault Equation)

The given text provides a formula to calculate CLCr, where CLCr denotes creatinine clearance in milliliters per minute. However, it is unclear what the units of weight are, as the word "weight" has a typo. Additionally, the formula has a typo in the second line, where "weignt" should be "weight". Without further context, it is not possible to provide a complete and accurate description.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This is a chart that shows the percentage of patients who showed improvement in pain levels from their baseline after taking different doses of pregabalin or a placebo. There are no non-English characters.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

The text is a graph which shows the percent of patients improved using Pregabalin 100mg three times a day as well as Placebo. The x-axis shows the levels of percent improvement in pain from baseline, while the y-axis shows the percentage of patients. The title of the graph is "Percent Improvement in Pain from Baseline". No further information about the study, the participants, or the purpose of the research was provided, so it is not possible to provide additional details.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This is a chart showing the percent of patients who improved on pregabalin at different dosages and a placebo. There is also a line chart demonstrating the percent improvement in pain from baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

The text shows a chart that displays the percentage of improvement in pain from baseline in patients taking Pregabalin and Placebo. The percentage ranges from 10 to 100, and the dosage of Pregabalin administered was either 100mg or 200mg, three times a day. The chart also indicates the percentage of patients who improved under each treatment.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

The text represents a table displaying the percent of patients who improved while taking Pregabalin and Placebo for pain relief. The patients were categorized based on the dosage of Pregabalin (50mg or 100mg, taken three times a day). The table also indicates the percent improvement in pain reported by patients.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This appears to be a table of data related to a study or trials involving different doses of a medication. The table includes columns for "Responder Rate (%)" and "BID" (which likely refers to the frequency of dosing, possibly "twice daily"). The table also includes references to "Study E1" and "Study E3" as well as different doses of the medication (ranging from 50mg/day to 600mg/day). Overall, it seems that higher doses of the medication may be more effective, with some showing statistically significant improvement compared to a placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This appears to be a chart or graph presenting statistical data with various doses and significant p-values. The data is related to a study or experiment involving different doses and the corresponding effects. The specific details of the study or experiment are not available.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

The text describes a chart that displays the percentage of patients who showed improvement in pain based on different doses of Pregabalin and Placebo. The chart range shows 1% to 100% with an interval of 10%. The text also mentions the doses of Pregabalin administered (600mg daily dose, 450mg daily dose, 300mg daily dose) and the Placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

The text provides a graph displaying the estimated percentage of subjects without LIR (location-independent residual) during a period of 180 days while taking Pregabalin and Placebo. The graph illustrates the percentages from 0% to 100% in increments of 10%, with the days from 80 to 180 on the horizontal axis. There is no additional information available.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

The text presents a graph showing the percentage of subjects improved from baseline to week 12 using Pregabalin compared to Placebo. The X-axis shows the percentage of improvement, ranging from 0 to 100, and the Y-axis represents the number of subjects. There is no additional information provided.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.